{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/5ffc1fe6b303132625aa8d15/696e3b9ff0f57e95a0fd5bbd?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"How can therapeutic drug monitoring and premedication be applied in clinical practice to optimize pegaspargase treatment in patients with ALL? ","description":"<p>The ALL Hub was pleased to speak with Carmelo Rizzari, University of Milano-Bicocca, Monza, IT. We asked, How can therapeutic drug monitoring and premedication be applied in clinical practice to optimize pegaspargase treatment in patients with acute lymphoblastic leukemia (ALL)? </p><p><br></p><p>This educational resource is independently supported by Servier. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.</p>","author_name":"Scientific Education Support"}